The Food and Drug Administration (FDA) issued draft guidance on clinical trial considerations to support accelerated approval of oncology therapeutics. The FDA asserts that while single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparison to an… (Slifer, March 24, 2023) #Food and Drug Administration, #Prescription Drugs